Novavax

-$0.83 (-1.45%) As of 12:13 PM UTC pre-market

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novavax and other ETFs, options, and stocks.

About NVAX

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.

CEO

Stanley C. Erck

Employees

1,541

Headquarters

Gaithersburg, Maryland

Founded

1987

NVAX Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

5.41M

High today

$57.55

Low today

$50.88

Open price

$51.96

Volume

6.42M

52 Week high

$277.80

52 Week low

$34.88

NVAX News

ReutersJul 1

Novavax expects COVID vaccine targeting Omicron in fourth quarter

July 1 (Reuters) - Novavax Inc said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates development of

BloombergJun 29

Bull Market Never Ended for Analysts Wedded to 100% Price Rally Calls

(Bloomberg) -- Whether it’s commendable courage or a refusal to face reality, a receding stock market tide has left Wall Street analysts sitting with price pred

MarketWatchJun 29

Novavax is part of the FDA’s COVID-19 booster debate, but its vaccine still hasn’t been authorized

Novavax’s NVAX, +0.96% COVID-19 vaccine candidate played a front-and-center role during this week’s debate about how best to update the COVID-19 boosters to bet

Analyst ratings

Buy

71.4%

Hold

14.3%

Sell

14.3%

NVAX Earnings

-$11.18

-$6.56

-$1.93

$2.69

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Aug 8, After Hours

More NVAX News

ReutersJun 29

Taiwan to receive first doses of Novavax COVID vaccine this week - Reuters

Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/